(Q74715799)

English

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690

scientific article published on 01 September 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

immunologic adjuvant

1 reference

based on heuristic

inferred from title

author name string

John M Kirkwood

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Thomas Richards

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Hassane M Zarour

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Jeffrey Sosman

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Marc Ernstoff

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Theresa L Whiteside

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Joseph Ibrahim

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Ronald Blum

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Samuel Wieand

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Ruth Mascari

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 September 2002

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

95

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1101-1112

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

A new American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Calculation of lytic units for the expression of cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10775

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10775

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q74715799&oldid=1779125144"